DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds

Stock Information for DiaMedica Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.